Can transfusion-associated graft-versus-host disease (TA-GvHD) be prevented with leukoreduction alone?
Source : https://www.trasci.com/article/S1473-0502(22)00064-7/fulltext
Transfusion-associated graft-versus-host disease (TA-GvHD) is a rare but devastating disease with a very high mortality rate. Because of the high mortality and lack of effective treatments, the current state of...
Conclusion/Relevance: “Given that TA-GvHD is driven by contaminating white blood cells, and the fact that the international transfusion community has largely embraced leukoreduction, this raises the question as to whether the quantitative reduction of leukocytes via filtration can itself prevent TA-GvHD, thus allowing hospitals to skip...
External Validation of the HIGH-2-LOW Model: A Predictive Score for Venous Thromboembolism after Allogeneic Transplant - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35266218/
In patients undergoing hematopoietic cell transplantation (HCT), venous thromboembolism (VTE) remains a serious complication that lacks validated risk assessment models (RAM) to guide thromboprophylaxis. To address this dilemma, we performed...
Conclusions: The HIGH-2-LOW RAM identified allogeneic HCT recipients at high-risk for VTE in both validation cohorts. It can improve evidence-based decision-making for thromboprophylaxis post-transplant.
The immunosuppressant drug Cyclosporin A aggravates irradiation effects in endothelial cells - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35272142/
The immunosuppressant drug Cyclosporin A (CsA) has been widely used to prevent the development of Graft-versus-Host Disease (GvHD) that can occur after transplantation, including allogeneic graft after accidental high-dose irradiation...
Conclusions: Altogether, these results suggest that post-transplant CsA treatment may exacerbate the deleterious effects of irradiation on the endothelium.
Low incidence of hyperacute graft-versus-host disease (GVHD) with effective GVHD prophylaxis based on anti-thymocyte globulin - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35245388/
doi: 10.1111/bjh.18099. Online ahead of print. 1 APHP, Hôpital Saint Antoine, Service d'Hématologie Clinique et de Thérapie cellulaire, Paris, France. 2 Clinical Hematology and Bone Marrow Transplant Centre, S. Maria...
Conclusion: Overall, development of new strategies such as RTC and generalisation of in vivo T-cell depletion with ATG and/or PTCy, translate into a decreased incidence of haGVHD. Furthermore, despite a higher incidence of cGVHD in patients with haGVHD compared to aGVHD after day 14, NRM and OS were similar. This suggests that patients with...
Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35246235/
doi: 10.1186/s13287-022-02751-0. 1 Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, The First Hospital of Jilin University, Changchun, 130061, China. 2 National-Local Joint Engineering Laboratory of Animal...
Conclusion: In this study, we attempted to analyze the clinical trials for MSCs in GVHD, identify the most suitable group of patients for MSC therapy, and provide a new perspective for the design of such trials in the future.